Drugs / DUOC-01
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04943289 | Jan 2021 → Sep 2025 | primary progressive multiple sclerosis | Joanne Kurtzberg, MD | Completed | No outcome recorded |
| Phase 1 | NCT02254863 | Sep 2014 → Oct 2026 expected | Krabbe disease, Niemann-Pick disease, Pelizaeus-Merzbacher spectrum disorder, Sandhoff disease +6 | Joanne Kurtzberg, MD | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DUOC-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04943289 ↗ |
| Modality | Cell therapy | “intrathecal administration of UCB-derived oligodendrocyte-like cells (DUOC-01)” NCT02254863 ↗ |
| Route | Intrathecal | “given intrathecally” NCT02254863 ↗ |